Senesco Technologies, Inc. FD Jack Van Hulst Brian Ritchie Chief Executive Officer (brian.ritchie@fd.com) (jvanhulst@senesco.com) (212) 850-5600 (732) 296-8400

INSIDERS ELECT CONVERSION PRICE FAVORABLE TO

RELATED TO SECURITIES PREVIOUSLY HELD BY STANFORD

BRUNSWICK, N.J. - March 5, 2010 -- Senesco Technologies, Inc. ("Senesco" or the

"Company") (NYSE Amex: SNT) reported today that the

insiders of the Company who had previously purchased all of the convertible

debentures, warrants and common stock of Senesco which were formerly held by

Stanford Venture Capital Holdings, Inc. have elected, subject to shareholder

approval, to convert the convertible debentures at a conversion price of

$0.83. Under the terms of the convertible debentures, such

convertible debentures could have converted at a floating conversion rate equal

to the lower of $0.83, or 80 percent of the lowest daily Volume-Weighted Average

Price (VWAP) for the five-day period immediately preceding the conversion date,

which equated to $0.22.

insiders had the option to convert at a lower price based on the VWAP, they

elected to convert at $0.83, which was the highest contractual conversion price

possible," said Harlan Waksal, M.D., Senesco's Chairman of the

Board. "This both minimizes shareholder dilution and strengthens

Senesco's balance sheet. As a company, we remain committed to

attracting sufficient financing and filing an IND for SNS-01, our multiple

myeloma drug candidate."

Senesco Technologies, Inc.

Senesco Technologies, Inc. is a U.S.

biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated

preclinical research to trigger or delay cell death in mammals (apoptosis) to

determine if the technology is applicable in human medicine. Accelerating

apoptosis may have applications to development of cancer treatments. Delaying

apoptosis may have applications to certain inflammatory and ischemic diseases.

Senesco takes its name from the scientific term for the aging of plant cells:

senescence. Delaying cell breakdown in plants extends freshness after

harvesting, while increasing crop yields, plant size and resistance to

environmental stress. The Company believes that its technology can be used to

develop superior strains of crops without any modification other than delaying

natural plant senescence. Senesco has partnered with leading-edge companies

engaged in agricultural biotechnology and earns research and development fees

for applying its gene-regulating platform technology to enhance its partners'

statements included in this press release are forward-looking statements within

the meaning of the Private Securities Litigation Reform Act of 1995. Actual

results could differ materially from such statements expressed or implied herein

as a result of a variety of factors, including, but not limited to: the ability

of the Company to consummate additional financings; the ability of the Company

to file an IND for SNS-01, its multiple myeloma drug candidate; the development

of the Company's gene technology; the approval of the Company's patent

applications; the successful implementation of the Company's research and

development programs and joint ventures; the success of the Company's license

agreements; the successful conversion of the Company's letter of intent into a

license agreement; the acceptance by the market of the Company's products;

success of the Company's preliminary studies and preclinical research;

competition and the timing of projects and trends in future operating

performance, as well as other factors expressed from time to time in the

Company's periodic filings with the Securities and Exchange Commission (the

"SEC"). As a result, this press release should be read in conjunction with the

Company's periodic filings with the SEC. The forward-looking statements

contained herein are made only as of the date of this press release, and the

Company undertakes no obligation to publicly update such forward-looking

statements to reflect subsequent events or circumstances.